
Thomas Gurry
@thomasgurry
Co-founder & CEO @myotahealth | translational #microbiome researcher specialised in fibre fermentation
ID: 791339323861983233
26-10-2016 18:02:52
321 Tweet
288 Followers
195 Following

Work with me! Biobot Analytics is hiring 2 software positions to build our product. If you want to: 📊 build a data platform to transform public health 🤓 work with a buncha cross-disciplinary nerds 💡 make foundational tech stack decisions Check us out! jobs.lever.co/biobot

Microbiome therapeutics and patent protection Nature Biotechnology nature.com/articles/s4158…

(1/2) Very excited to share our latest paper out at Science Magazine on microbiota-derived inosine and its role in cancer immune checkpoint blockade therapy. science.sciencemag.org/content/early/…




Wonderful work Jessica R Allegretti Colleen Kelly Ari Grinspan Ben Mullish - a monumental lift, and highlights the safety of microbiome therapeutics in IBD patients with concomitant CDI


Really nice work from Vinod Gupta, Jaeyun Sung, PhD et al. at the Mayo Clinic introducing the Gut Microbiome Health Index (GMHI), calculated from stool metagenomic sequencing data, as a predictor of disease independent of clinical indication: doi.org/10.1038/s41467…

Biobot Analytics is growing our data team and we're hiring! Join us as Head of Data to: 🌳 structure & grow our data team 🤓 nurture a company-wide data-driven culture 📊 solidify Biobot as a leader in public health data science Check it out! jobs.lever.co/biobot/6bf53db…




Just out The Lancet: Largest study of reinfection, whole country of Denmark —0.65% after prior covid —Protection ~80%, lasts ≥ 7 months —Age ≥ 65 protection reduced to 47% thelancet.com/journals/lance… Steen Ethelberg University of Copenhagen Statens Serum Institut





